(Reuters) -BillionToOne filed for an initial public offering in the United States on Tuesday. The company’s filing comes at a time when U.S. IPO activity is picking up, reversing a slowdown from earlier in the year, when trade-policy uncertainty curbed momentum. The Menlo Park, California-based precision diagnostics company will list on the Nasdaq under the […]
Health
Molecular diagnostics firm BillionToOne files for US IPO
Audio By Carbonatix
(Reuters) -BillionToOne filed for an initial public offering in the United States on Tuesday.
The company’s filing comes at a time when U.S. IPO activity is picking up, reversing a slowdown from earlier in the year, when trade-policy uncertainty curbed momentum.
The Menlo Park, California-based precision diagnostics company will list on the Nasdaq under the “BLLN” ticker symbol.
BillionToOne develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for diseases.
It reported revenue of $125.5 million in the first half of 2025, compared with $69 million in the year-ago period, according to the IPO filing.
Net loss narrowed to $4.2 million in the six months ended June 30, from a loss of $15.2 million in the same period last year.
J.P. Morgan, Wells Fargo and William Blair are among the underwriters for the offering.
(Reporting by Aatreyee Dasgupta in Bengaluru; Editing by Alan Barona)